 |
|
Treatment Selection in Ductal Carcinoma In Situ
Monica Morrow, MD;
Stuart J. Schnitt, MD
JAMA. 2000;283:453-455.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
INTRODUCTION
Ductal carcinoma in situ (DCIS) is a proliferation of presumably malignant epithelial cells within the mammary ductal-lobular system without evidence of invasion. In the past, DCIS was uncommon, accounting for only 2% of 10,000 cancer cases treated in 1980.1 Between 1973 and 1992, age-adjusted DCIS incidence rates increased by 587%, while the incidence of invasive carcinoma increased by 34.3%.2 This increase was almost entirely confined to women older than 40 years and is thought to be due to the increased use of screening mammography. This has led to speculation that screening mammography may detect biologically indolent DCIS that is unlikely to become clinically significant.2
However, several lines of evidence argue against this. Risk factors for DCIS and invasive carcinoma are similar, suggesting a common origin.3 Autopsy studies in women not known to have had breast cancer demonstrate DCIS in 0.2% to 18% of . . . [Full Text of this Article]
Local Therapy
The Role of Tamoxifen
Treatment Selection for the Individual Patient
Author Affiliations: Department of Surgery and Lynn Sage Comprehensive Breast Center, Northwestern University Medical School, Chicago, Ill (Dr Morrow); Department of Pathology, Beth Israel Hospital, Harvard Medical School, Boston, Mass (Dr Schnitt).
RELATED ARTICLE
January 26, 2000
JAMA. 2000;283(4):547-548.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Trends in the Treatment of Ductal Carcinoma In Situ of the Breast
Baxter et al.
JNCI J Natl Cancer Inst 2004;96:443-448.
ABSTRACT
| FULL TEXT
|
